Delivery of insulin to the buccal mucosa utilizing the RapidMist system

Abstract

Background: The burgeoning number of people with diabetes mellitus is a global problem. Simple but effective treatment with minimal side effects will be required to reduce the risk for macro- and micro-vascular complications. A big part of this goal can be achieved by the ready administration of insulin with or without other medications.

Methods: The RapidMist drug delivery system places human recombinant insulin in a liquid formulation so as to be delivered to the buccal mucosa with an asthma-like device. As with nitroglycerin, the insulin PK-PD is very fast, thus affording flexibility.

Conclusion: Serial data show clinical efficacy in Type 1 and Type 2 diabetes with at least non-inferiority to regular insulin.